Proteomic identification of serum biomarkers for head and neck cancer surveillance

Christine G. Gourin, Wenbo Zhi, Bao Ling Adam

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objectives/Hypothesis: Serum protein profiling by SELDI-TOF-MS distinguishes pretreatment and post-treatment samples from patients with head and neck squamous cell cancer (HNSCC) by disease status (disease-free or recurrence) with a high degree of sensitivity and specificity. We sought to identify biomarkers for recurrence with potential utility for surveillance and incorporated 2-D DIGE and MALDI-TOF-MS techniques to overcome the limitations of SELDI-TOF-MS in determining biomarker identity. Methods: Serum samples were collected prospectively from 143 HNSCC patients and analyzed based on disease status following treatment. Results: Recurrent HNSCC occurred in 46 patients. MALDI-TOF-MS following immunodepletion of major plasma proteins followed by 2-D DIGE identified 181 proteins with differential expression between pretreatment and post-treatment samples collected 6 months or more following treatment. Classification by disease status revealed significant differential expression of 16 proteins, with recurrent HNSCC associated with underexpression of kininogen and serine protease inhibitors C-1 inhibitor, kininogen, angiotensinogen, serine/cysteine proteinase inhibitor clade G member 1, and overexpression of thiol-specific antioxidant proteins (TSA), apolipoprotein A1 and proapolipoprotein, and epidermal cytokeratin 2. Conclusions: Serum protein profiling using 2D DIGE/MALDI-TOF-MS identifies proteins with significant differential expression in HNSCC based on disease status. Recurrent HNSCC was associated with underexpression of several protease inhibitors and kininogen, which has antiangiogenic properties, and overexpression of TSA, which is a free radical scavenger, as well as several forms of apolipoprotein A1 that may serve as a carrier molecule but may also indirectly promote tumor survival through kinase activation. This profile is consistent with a more aggressive disease variant and warrants further investigation.

Original languageEnglish (US)
Pages (from-to)1291-1302
Number of pages12
JournalLaryngoscope
Volume119
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Squamous Cell Neoplasms
Head and Neck Neoplasms
Proteomics
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Biomarkers
Head
Kininogens
Serum
Peroxiredoxins
Blood Proteins
Serine Proteinase Inhibitors
Apolipoprotein A-I
Keratin-2
Two-Dimensional Difference Gel Electrophoresis
Cysteine Proteinase Inhibitors
Recurrence
Angiotensinogen
Free Radical Scavengers
Proteins
Therapeutics

Keywords

  • Head and neck neoplasms
  • Proteomics
  • Recurrence
  • Serum
  • Squamous cell cancer

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Proteomic identification of serum biomarkers for head and neck cancer surveillance. / Gourin, Christine G.; Zhi, Wenbo; Adam, Bao Ling.

In: Laryngoscope, Vol. 119, No. 7, 01.07.2009, p. 1291-1302.

Research output: Contribution to journalArticle

Gourin, Christine G. ; Zhi, Wenbo ; Adam, Bao Ling. / Proteomic identification of serum biomarkers for head and neck cancer surveillance. In: Laryngoscope. 2009 ; Vol. 119, No. 7. pp. 1291-1302.
@article{c4afba94d5cf4645aa63a391b401f5e8,
title = "Proteomic identification of serum biomarkers for head and neck cancer surveillance",
abstract = "Objectives/Hypothesis: Serum protein profiling by SELDI-TOF-MS distinguishes pretreatment and post-treatment samples from patients with head and neck squamous cell cancer (HNSCC) by disease status (disease-free or recurrence) with a high degree of sensitivity and specificity. We sought to identify biomarkers for recurrence with potential utility for surveillance and incorporated 2-D DIGE and MALDI-TOF-MS techniques to overcome the limitations of SELDI-TOF-MS in determining biomarker identity. Methods: Serum samples were collected prospectively from 143 HNSCC patients and analyzed based on disease status following treatment. Results: Recurrent HNSCC occurred in 46 patients. MALDI-TOF-MS following immunodepletion of major plasma proteins followed by 2-D DIGE identified 181 proteins with differential expression between pretreatment and post-treatment samples collected 6 months or more following treatment. Classification by disease status revealed significant differential expression of 16 proteins, with recurrent HNSCC associated with underexpression of kininogen and serine protease inhibitors C-1 inhibitor, kininogen, angiotensinogen, serine/cysteine proteinase inhibitor clade G member 1, and overexpression of thiol-specific antioxidant proteins (TSA), apolipoprotein A1 and proapolipoprotein, and epidermal cytokeratin 2. Conclusions: Serum protein profiling using 2D DIGE/MALDI-TOF-MS identifies proteins with significant differential expression in HNSCC based on disease status. Recurrent HNSCC was associated with underexpression of several protease inhibitors and kininogen, which has antiangiogenic properties, and overexpression of TSA, which is a free radical scavenger, as well as several forms of apolipoprotein A1 that may serve as a carrier molecule but may also indirectly promote tumor survival through kinase activation. This profile is consistent with a more aggressive disease variant and warrants further investigation.",
keywords = "Head and neck neoplasms, Proteomics, Recurrence, Serum, Squamous cell cancer",
author = "Gourin, {Christine G.} and Wenbo Zhi and Adam, {Bao Ling}",
year = "2009",
month = "7",
day = "1",
doi = "10.1002/lary.20279",
language = "English (US)",
volume = "119",
pages = "1291--1302",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Proteomic identification of serum biomarkers for head and neck cancer surveillance

AU - Gourin, Christine G.

AU - Zhi, Wenbo

AU - Adam, Bao Ling

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Objectives/Hypothesis: Serum protein profiling by SELDI-TOF-MS distinguishes pretreatment and post-treatment samples from patients with head and neck squamous cell cancer (HNSCC) by disease status (disease-free or recurrence) with a high degree of sensitivity and specificity. We sought to identify biomarkers for recurrence with potential utility for surveillance and incorporated 2-D DIGE and MALDI-TOF-MS techniques to overcome the limitations of SELDI-TOF-MS in determining biomarker identity. Methods: Serum samples were collected prospectively from 143 HNSCC patients and analyzed based on disease status following treatment. Results: Recurrent HNSCC occurred in 46 patients. MALDI-TOF-MS following immunodepletion of major plasma proteins followed by 2-D DIGE identified 181 proteins with differential expression between pretreatment and post-treatment samples collected 6 months or more following treatment. Classification by disease status revealed significant differential expression of 16 proteins, with recurrent HNSCC associated with underexpression of kininogen and serine protease inhibitors C-1 inhibitor, kininogen, angiotensinogen, serine/cysteine proteinase inhibitor clade G member 1, and overexpression of thiol-specific antioxidant proteins (TSA), apolipoprotein A1 and proapolipoprotein, and epidermal cytokeratin 2. Conclusions: Serum protein profiling using 2D DIGE/MALDI-TOF-MS identifies proteins with significant differential expression in HNSCC based on disease status. Recurrent HNSCC was associated with underexpression of several protease inhibitors and kininogen, which has antiangiogenic properties, and overexpression of TSA, which is a free radical scavenger, as well as several forms of apolipoprotein A1 that may serve as a carrier molecule but may also indirectly promote tumor survival through kinase activation. This profile is consistent with a more aggressive disease variant and warrants further investigation.

AB - Objectives/Hypothesis: Serum protein profiling by SELDI-TOF-MS distinguishes pretreatment and post-treatment samples from patients with head and neck squamous cell cancer (HNSCC) by disease status (disease-free or recurrence) with a high degree of sensitivity and specificity. We sought to identify biomarkers for recurrence with potential utility for surveillance and incorporated 2-D DIGE and MALDI-TOF-MS techniques to overcome the limitations of SELDI-TOF-MS in determining biomarker identity. Methods: Serum samples were collected prospectively from 143 HNSCC patients and analyzed based on disease status following treatment. Results: Recurrent HNSCC occurred in 46 patients. MALDI-TOF-MS following immunodepletion of major plasma proteins followed by 2-D DIGE identified 181 proteins with differential expression between pretreatment and post-treatment samples collected 6 months or more following treatment. Classification by disease status revealed significant differential expression of 16 proteins, with recurrent HNSCC associated with underexpression of kininogen and serine protease inhibitors C-1 inhibitor, kininogen, angiotensinogen, serine/cysteine proteinase inhibitor clade G member 1, and overexpression of thiol-specific antioxidant proteins (TSA), apolipoprotein A1 and proapolipoprotein, and epidermal cytokeratin 2. Conclusions: Serum protein profiling using 2D DIGE/MALDI-TOF-MS identifies proteins with significant differential expression in HNSCC based on disease status. Recurrent HNSCC was associated with underexpression of several protease inhibitors and kininogen, which has antiangiogenic properties, and overexpression of TSA, which is a free radical scavenger, as well as several forms of apolipoprotein A1 that may serve as a carrier molecule but may also indirectly promote tumor survival through kinase activation. This profile is consistent with a more aggressive disease variant and warrants further investigation.

KW - Head and neck neoplasms

KW - Proteomics

KW - Recurrence

KW - Serum

KW - Squamous cell cancer

UR - http://www.scopus.com/inward/record.url?scp=67949103390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67949103390&partnerID=8YFLogxK

U2 - 10.1002/lary.20279

DO - 10.1002/lary.20279

M3 - Article

VL - 119

SP - 1291

EP - 1302

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 7

ER -